93 studies (1 from unattributed sources) on MK-677 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Qingdao Sigma Chemical | 2 | 96.0% | View COA → |
| Strate Labs Canada | 2 | — | View COA → |
Recent certificates: #9084 (93.37%) · #20703 (98.0%) · #14340 (96.0%) · #22892 (98.0%)
Manufacturers with published third-party certificates of analysis for MK-677. Open a vendor to see every batch we've verified.
This case report highlights a critical, rare, and potentially life-threatening complication associated with the use of performance-enhancing compounds. It underscores the importance for clinicians to consider ASR in p…
Alzheimer's Disease remains a significant unmet medical need, and exploring novel therapeutic avenues is crucial. MK-0677, known as a growth hormone secretagogue (a compound that stimulates the secretion of growth hor…
The potential for an oral GH secretagogue like MK-677 to restore youthful GH and IGF-I levels in older adults holds significant promise for combating age-related decline. If successful, this intervention could improve…
The prevalence of NAFLD and NASH is alarmingly high, and effective pharmacological treatments are scarce, making the exploration of new therapies critical. Positive findings from this pilot study could position Ibutam…
The withdrawal of this study means a significant opportunity was missed to explore a potential therapeutic avenue for muscle wasting in advanced CKD. Sarcopenia in CKD patients is a major predictor of morbidity and mo…
This research provides crucial, mechanistic insight into the direct neural targets of nonpeptide growth hormone secretagogues like MK-0677. Understanding how these compounds specifically activate neurons in the arcuat…
Why It Matters This study provides the first definitive evidence for specific, high-affinity GH secretagogue receptors in key human tissues, fundamentally advancing our understanding of how these compounds exert their…
This research highlights that MK-677 actively engages bone metabolism, accelerating both the building and breakdown phases. This dual effect suggests that while it stimulates bone activity, the net impact on bone mine…
The discovery of potent, orally active Growth Hormone (GH) secretagogues like compound 18 is highly significant because it offers a non-invasive alternative to injectable peptide-based therapies. Such compounds could …
The discovery of spiro(3H-1-benzopyran-2,3-piperidine), exhibiting low nanomolar potency, represents a significant breakthrough in the ongoing search for novel growth hormone secretagogues. This compound's high activi…
This early review was pivotal in identifying a novel therapeutic strategy for addressing growth and endocrine complications in thalassemia. By proposing the use of GH secretagogues, the authors opened a new direction …
This research is significant because it definitively establishes the pituitary-dependent mechanism of MK-0677. Understanding this mechanism is crucial for developing and safely utilizing growth hormone secretagogues, …
This finding is significant because it suggests that systemic administration of GH or GH secretagogues may not directly influence GH/IGF-1 signaling within the brain, at least not via increased CSF concentrations. Thi…
This research highlights the significant potential of structural modifications to enhance the pharmacological profile of existing GHS. Identifying more potent analogues like NN703-S12 could lead to the development of …
This research highlights that MK-677 can significantly modulate lipoprotein profiles in obese individuals, demonstrating its potential metabolic activity beyond just growth hormone stimulation. The observed reductions…
MK-677's ability to increase bone turnover markers suggests its potential role in combating age-related bone loss and improving overall bone health. While an initial increase in both formation and resorption might see…
This research provides compelling evidence that human pituitary adenomas express functional growth hormone secretagogue receptors, which can directly influence hormone secretion. This discovery is crucial because it s…
This study provides crucial insights into the neurobiological mechanisms underlying chronic GHS action, particularly their influence on hypothalamic circuits regulating energy balance. The observed upregulation of ore…
This research highlights the complex neuroendocrine regulation of growth hormone secretagogue action within the hypothalamus. Understanding these interactions could be crucial for developing more targeted therapies fo…
This research highlights a novel mechanism by which MK-677 may influence metabolic pathways, specifically by altering the tightly regulated relationship between leptin and body fat. Understanding this discrepancy is c…
This comprehensive review was instrumental in solidifying the understanding of the GHSR-1a pathway as a major regulator of GH secretion, independent of GHRH. The identification of orally active, non-peptidic GHS like …
This review significantly expanded the understanding of GHS pharmacology, moving beyond their traditional role in GH deficiency. The identification of diverse non-endocrine actions, such as effects on appetite, metabo…
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements an…
This landmark review fundamentally reshaped the understanding of GH modulation, establishing GHSs as a powerful and physiologically relevant therapeutic strategy. By stimulating endogenous GH, GHSs offered a pathway t…
This research significantly advances our understanding of how growth hormone secretagogues (GHS) exert their effects on the brain, revealing a novel, non-noradrenergic signaling pathway. This discovery is crucial beca…
This research provides crucial analytical and preparative separation techniques essential for the development of new growth hormone secretagogue drugs. By enabling the purification of individual diastereomers, it allo…
This review critically highlights the therapeutic potential of GHRPs beyond their established GH-releasing properties, suggesting they could be novel pharmacological agents for treating various cardiovascular diseases…
This review was crucial in its time for mapping out nascent drug development pathways, providing a roadmap for future research. The identification of targets like growth hormone secretagogue receptor agonists and Nurr…
This discovery fundamentally expands our understanding of GHSR regulation beyond ghrelin, suggesting a broader physiological role for this receptor. It implies that adenosine, a ubiquitous signaling molecule involved …
The findings suggest that GHS represent a promising therapeutic strategy for combating age-related decline in GH and IGF-1, potentially improving body composition and overall vitality in older adults. By stimulating e…
The study successfully identified adenosine as a partial agonist of the GHS-R, meaning it can activate the receptor but not to its full potential. Activation of GHS-R by adenosine was significantly inhibited by select…
This groundbreaking research significantly expands our understanding of GHS physiology, indicating that these compounds, and potentially the endogenous ligand ghrelin, have direct actions on multiple peripheral organs…
This study's findings are profoundly significant as they demonstrate that combining an antiresorptive agent like alendronate with a growth hormone secretagogue such as MK-677 can yield superior improvements in bone mi…
This study provides critical direct evidence for the presence of ghrelin receptors in key human brain regions, specifically the hypothalamus and pituitary gland, which are central to regulating appetite, energy homeos…
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the b…
This foundational review consolidated critical knowledge about the GHS-R system, providing a robust framework that significantly influenced subsequent research and drug discovery efforts. It highlighted the immense po…
This research is significant because it highlights the complex interplay between hexarelin and different cardiac cell types, specifically emphasizing the often-overlooked role of endothelial cells in mediating drug ef…
This study highlights SM-130686 as a potent, selective, and orally active growth hormone secretagogue. Its ability to significantly boost GH levels and improve lean body mass in an animal model suggests considerable t…
The identification of SM-130686 (37S) represents a significant step forward, as it is an orally active, highly potent growth hormone secretagogue with a favorable pharmacokinetic profile in rats. Its ability to induce…
This research highlights a novel and potentially significant role for synthetic peptidyl GH secretagogues beyond their traditional endocrine functions, suggesting they could be repurposed as direct anticancer agents. …
This comprehensive review highlights ghrelin's multifaceted nature, demonstrating it is far more than just a GH secretagogue. Understanding ghrelin's broad actions opens new avenues for therapeutic development and dru…
The discovery of capromorelin represents a significant advancement in the development of orally active Growth Hormone Secretagogues (GHSs). Its excellent bioavailability and oral activity directly address a major hurd…
The administration of MK-677 led to significant and sustained increases in overall growth hormone (GH) secretion. Specifically, the study observed pronounced elevations in both the 22 kDa and 20 kDa GH isoforms, which…
Free, no account — handy when you're working with MK-677.